Collaborative evidence generation to advance best practices in healthcare
We are investing in evidence-based medicine to improve outcomes
Since 1970, Varian has been investing in the science behind our products. With more than 300 active and approved comprehensive research collaborations and clinical trials, we are generating evidence across radiotherapy modalities such as proton therapy, proton FLASH therapy, adaptive radiotherapy, and cardiac radioablation; interventional modalities including embolization; and advanced imaging systems plus AI-powered support tools. Our goal is to empower clinicians to be more precise and make more informed decisions, enabling them to deliver the right care at the right time, fighting for a world without fear of cancer.
Working together to improve survivor outcomes in cancer care
Trends driving increased survivorship
- Earlier diagnosis
- New technologies / advancements
- Patient awareness
- Screening and Dx
5-year overall survival
*Forecasted survival rate based on increases in treatment efficacy (Phase 213 data) and liquid biopsy availability. Artificial lungs. livers. and pancreas are under development but are not expected to be commercialized by 2027.
Sources: Survival Data: (1) National Cancer Institute’s SEER*Stat 8.3.4 databases, (2) Genomic Health Clinical Validation Trials, (3) Roche IMpassion 130 trial, additional on file.
Investing in evidence-based medicine
Evidence generation to drive advances in standard of care
Adaptive Radiotherapy
Ongoing Ethos trials focusing on different disease sites and clinical scenarios
disease sites
planned participants
trials
institutions
Advanced Imaging
Ongoing & committed trials
HyperSight on Halcyon/Ethos
HyperSight on TrueBeam
trials
planned participants
institutions
Cardiac RadioAblation
Multi-institutional, multi-national randomized controlled clinical trial
planned participants
institutions
Interventional Radiology
Ongoing & committed clinical trials
trials
planned participants
Proton Flash Therapy
Ongoing & committed clinical trials
participants treated
FAST 01
participants planned
FAST 01
FAST-01 results in JAMA Oncology
FAST-01 trial cited by Physics World’s as a Top 10 Breakthrough of 2022
Evidence that Demonstrates Value
Working collaboratively with cancer care teams, institutions, and societies across the globe, we help contribute to the body of knowledge about cancer treatment technologies and advancements across many treatment areas.
Adaptive Radiotherapy
Ongoing increase in adaptive publications
Since 1997, over 1600 peer-reviewed publications using adaptive radiotherapy have appeared in various clinical journals, and the number is growing. They include: randomized studies, systematic reviews, real world evidence analysis, prospective and retrospective comparison studies, pre-clinical studies.
Number of publications mentioning adaptive radiotherapy
Multi-institutional, multi-national Ethos clinical trials across disease sites and clinical scenarios:
Investigator-led adaptive studies:
Cardiac Radioablation
Multi-institutional, multi-national randomized controlled clinical trial
Autocontouring
Clinical evaluations of AI based autocontouring
Resources
- Evaluation of a deep image-to-image network (DI2IN) auto-segmentation algorithm across a network of cancer centers
- Multicenter Study of Pelvic Nodal Autosegmentation Algorithm of Siemens Healthineers: Comparison of Male Versus Female Pelvis
- Multi-Institutional Study to Evaluate an AI Algorithm for Auto-Segmentation of the Head and Neck Nodal Contouring